Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $70 from $62 and keeps an Overweight rating on the shares. The firm has updated its Boston Scientific model for the acquisition for Axonics (AXNX), which the company expects to close in the first half of 2024. Wells models the deal being 1c dilutive to its 2024 EPS and accretive thereafter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific named 2024 Top Pick in MedTech at RBC Capital
- Axonics downgraded to Neutral from Overweight at Piper Sandler
- NeuroPace price target raised to $17 from $12 at Lake Street
- Axonics downgraded to Peer Perform from Outperform at Wolfe Research
- Unusually active option classes on open January 8th